PRESS RELEASE published on 11/27/2024 at 23:05, 1 year 4 months ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 1 year 4 months ago Theralase Technologies conclut un placement privé de 666 400 $CAN Placement Privé Cancer De La Vessie Technologies Théralase Mandats Stade Clinique
BRIEF published on 11/15/2024 at 13:05, 1 year 4 months ago Theralase Technologies Concludes Private Placement of $CAN 666,400 Private Placement Warrants Bladder Cancer Theralase Technologies Clinical Stage
PRESS RELEASE published on 11/15/2024 at 13:00, 1 year 4 months ago Theralase(R) Closes Non-Brokered Private Placement Theralase® Technologies Inc. successfully closes non-brokered private placement offering of units for cancer research and development funding Private Placement Offering Drug Development Clinical Study Cancer Research Theralase® Technologies Inc.
BRIEF published on 11/13/2024 at 00:28, 1 year 4 months ago Theralase Technologies Extends Warrant Expiry to 2027 TSX Venture Exchange Warrant Extension Cancer Treatment Theralase Technologies Pharmaceutical Development
BRIEF published on 11/13/2024 at 00:28, 1 year 4 months ago Theralase Technologies prolonge l'expiration du mandat jusqu'en 2027 Bourse De Croissance TSX Traitement Du Cancer Technologies Théralase Développement Pharmaceutique Prolongation Du Mandat
PRESS RELEASE published on 11/13/2024 at 00:23, 1 year 4 months ago Theralase(R) Extends Warrants Theralase® Technologies Inc. intends to extend the expiry date of 1,000,000 share purchase warrants from Nov 17, 2024, to Nov 17, 2027. This extension is subject to TSXV approval TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 10/07/2024 at 13:05, 1 year 5 months ago Mises à jour de Theralase sur l'étude clinique sur le cancer de la vessie Approbation De La FDA Étude Clinique Theralase Cancer De La Vessie Ruvidar
BRIEF published on 10/07/2024 at 13:05, 1 year 5 months ago Theralase Updates on Bladder Cancer Clinical Study FDA Approval Clinical Study Theralase Bladder Cancer Ruvidar
PRESS RELEASE published on 10/07/2024 at 13:00, 1 year 5 months ago Theralase(R) Provides Update on Bladder Cancer Clinical Study Theralase® Technologies Inc. provides update on bladder cancer clinical study for BCG-Unresponsive NMIBC CIS using Ruvidar™ drug activated by TLC-3200 Medical Laser System, achieving positive interim results Clinical Study Theralase® Bladder Cancer RuvidarTM BCG-Unresponsive
Published on 04/01/2026 at 04:06, 1 hour 29 minutes ago Jaguar Mining Reports Financial Results for the Fourth Quarter and Full Year 2025
Published on 04/01/2026 at 03:57, 1 hour 38 minutes ago NXT Energy Solutions Announces 2025 Year-End Results
Published on 04/01/2026 at 03:10, 2 hours 25 minutes ago Jaguar Mining Reports Updated Significant 49% Increase in Mineral Reserves at Pilar Mine, Reinforcing Long Term Growth Strategy
Published on 04/01/2026 at 01:40, 3 hours 55 minutes ago Thunder Rock Capital Serves as Exclusive Financial Advisor in Crown Reserve Acquisition Corp. I's Proposed $1.0 Billion Business Combination with Carvix, Inc.
Published on 04/01/2026 at 00:15, 5 hours 19 minutes ago Mesabi Metallics Secures $520 Million from Breakwall Capital - Advances towards Q3 2026 start of New American Iron Ore Mine
Published on 03/31/2026 at 23:05, 6 hours 29 minutes ago DeFi Technologies Announces Preliminary Unaudited Full Year 2025 Financial Results with Record Revenue of $99.1 Million and Record Net Income of $62.7 Million; Appoints New Independent Chair of the Audit Committee
Published on 03/31/2026 at 22:15, 7 hours 20 minutes ago Amrize Appoints Baris Oran as Chief Financial Officer
Published on 03/31/2026 at 20:30, 9 hours 5 minutes ago Press release: General Meeting approves all proposals – Markus Schürch elected new Chairman of the Board of Directors
Published on 03/31/2026 at 20:08, 9 hours 26 minutes ago SMTPC - Communiqué sur les résultats annuels 2025
Published on 03/31/2026 at 19:05, 10 hours 29 minutes ago SFPI GROUP: implementation of a new liquidity contract
Published on 03/31/2026 at 19:05, 10 hours 29 minutes ago Groupe SFPI : mise en oeuvre d'un nouveau contrat de liquidité
Published on 03/31/2026 at 19:00, 10 hours 35 minutes ago COGRA : Transfert du contrat de liquidité chez TSAF
Published on 03/31/2026 at 18:34, 11 hours ago Damartex / Transfert du contrat de liquidité auprès du Crédit Industriel et Commercial
